New pneumococcal 15-valent conjugate vaccine that includes coverage against serotype 3

Description

In this Product Explainer, Public Health Physician and Infectious Diseases Epidemiologist Prof Paul Van Buynder explains the burden of pneumococcal disease in both children and adult population. He explains why PCV 15 has increased serotype coverage and why improved immunogenicity against serotype 3 is important both from a clinical and public health perspective (5 mins).

Icon 2

NEXT LIVE Webcast

:
Days
:
Hours
:
Minutes
Seconds
Dr Kate Walsh

Dr Kate Walsh

Endometriosis Cases – Practical Guide

Prof Finlay Macrae AO

Prof Finlay Macrae AO

Familial Colorectal Cancer

Prof Richard Harvey

Prof Richard Harvey

Recurrent Nasal Polyps Management – When to Refer

Prof Terence O'Brien

Prof Terence O'Brien

SUDEP – What is it and How to Reduce the Risk

Join us for the next free webcast for GPs and healthcare professionals

High quality lectures delivered by leading independent experts

Prof Paul Van Buynder

expert

Prof Paul Van Buynder

Public Health Physician and Infectious Diseases Epidemiologist; Professor, School of Medicine, Griffith University, Queensland

Date published: 1 January 1970